EFFICACY OF 5 MG AND 10 MG XXXX IN TYPE-2 DIABETES MELLITUS WITH HYPERCHOLESTEROALEMIA.

@entity1 @entity1007 @entity6 @entity301 @entity8671 @entity11429 @entity3918 @entity204 @entity6817 @entity165
BACKGROUND: @entity301 ( @entity301 ) is the most important complication and the leading cause of @entity204 in @entity1 with @entity6 ( @entity6 ). @entity1007 is an important modifiable risk factor for @entity301 . Statins are the first line drugs for the treatment of @entity1007 in @entity3918 . Comparative studies between different statins are available but different doses of the same @entity6817 have not been compared in our population. The objective of this study is to compare mean reduction in serum @entity11429 level after using 5mg and 10mg of @entity8671 among @entity6 @entity1 with @entity1007 . This study will help finding lowest effective dose of @entity8671 to achieve internationally set low density lipoprotein @entity165 ( @entity11429 ) goals. METHODS: A total of 82 @entity1 with @entity6 having fasting @entity11429 levels equal or more than 100mg/dl were randomly allocated into two groups with 41 @entity1 in each group. Baseline fasting serum LCL-C levels were obtained in all @entity1 . Group A received 5mg while group B received 10mg of @entity8671 daily at night. After 6 weeks, fasting @entity11429 levels were obtained and analysed to compare the mean  SD reduction of @entity11429 levels in both groups. RESULTS: Baseline mean  SD @entity11429 levels in group A and group B were 134.12  30.02 and 143.49  32.01 respectively (p 0.176). Follow up mean  SD @entity11429 levels were 81.59  28.47 and 83.24  36.06respectively (p 0.818). Mean  SD reduction in @entity11429 levels from baseline levels in group A and group B were 52.51  19.49 and 60.20  24.09 (p 0.116). CONCLUSION: @entity8671 5mg is as effective as 10mg in reducing the @entity11429 levels in type 2 @entity6 @entity1 with @entity1007 .
